Ekso Bionics (NASDAQ:EKSO) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com assumed coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a research note issued on Friday. The brokerage set a “hold” rating on the stock.

Several other research firms have also recently weighed in on EKSO. HC Wainwright reaffirmed a “buy” rating and set a $9.00 price objective on shares of Ekso Bionics in a research report on Tuesday, March 4th. Lake Street Capital reduced their price target on shares of Ekso Bionics from $2.00 to $1.00 and set a “buy” rating on the stock in a research report on Tuesday, March 4th.

Ekso Bionics Trading Down 9.7 %

EKSO stock opened at $0.38 on Friday. Ekso Bionics has a one year low of $0.34 and a one year high of $1.53. The stock has a market cap of $9.38 million, a price-to-earnings ratio of -0.58 and a beta of 1.33. The company has a fifty day moving average price of $0.50 and a two-hundred day moving average price of $0.71. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.81 and a quick ratio of 2.14.

Ekso Bionics (NASDAQ:EKSO) last issued its quarterly earnings data on Monday, March 3rd. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.07). Ekso Bionics had a negative return on equity of 83.09% and a negative net margin of 62.95%. The company had revenue of $5.09 million for the quarter, compared to analyst estimates of $5.05 million. Equities analysts anticipate that Ekso Bionics will post -0.48 EPS for the current year.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.